Abstract
Background: Melphalan (L-PAM) hyperthermic isolated limb perfusion (HILP) is currently considered the standard treatment for patients with in-transit metastases from cutaneous melanoma. We here report on the results of L-PAM and low-dose tumor necrosis factor (TNF)α HILP in patients with bulky disease.
Methods: Twenty patients underwent TNFα (1 mg) and L-PAM (10 mg/L) HILP. Perfusion was performed for 90 minutes, and systemic leakage was strictly monitored. Locoregional toxicity was evaluated according to Wieberdink’s criteria, whereas tumor response was evaluated with physical examination and ultrasound scan with or without fine-needle aspiration of any suspected recurrence.
Results: In all cases, systemic leakage was <5%. No postoperative deaths occurred, and locoregional toxicity was mild (grade 1 or 2) in 95% of patients. A complete tumor response was obtained in 14 patients (70%), and partial responses were obtained in 5 patients (25%). After a median follow-up of 18 months, six patients are alive and disease free, seven are alive with local or distant recurrence or both, and seven have died of disease.
Conclusions: Low-dose TNFα HILP can achieve tumor responses comparable with those reported with higher doses of cytokine. Moreover, this drug regimen is associated with acceptable local toxicity, carries a smaller risk of systemic toxicity, and incurs lower costs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Borgstein PJ, Meijer S, van Diest PJ. Are locoregional cutaneous metastases in melanoma predictable?. Ann Surg Oncol 1999;6:315–321.
Wong JH, Cagle LA, Kopald KH, Swisher SG, Morton DL. Natural history and selective management of in transit melanoma. J Surg Oncol 1990;44:146–150.
Fraker DL. Hyperthermic regional perfusion for melanoma and sarcoma of the limbs. Curr Probl Surg 1999;36:841–907.
Rossi CR, Foletto M, Pilati P, Mocellin S, Lise M. Isolated limb perfusion in locally advanced cutaneous melanoma. Semin Oncol 2002;29:400–409.
Allen RE Jr. Systemic leakage and side effects of tumor necrosis factor alpha administration via isolated limb perfusion can be manipulated by flow rate adjustment. Arch Surg 1996;131:220.
Kroon BB, Noorda EM, Vrouenraets BC, Nieweg OE. Isolated limb perfusion for melanoma. J Surg Oncol 2002;79:252–255.
Steinmann G. An open, randomized prospective trial to compare the efficacy and safety of TNFalpha 1a and melphalan with melphalan alone via isolated limb perfusion for metastatic melanoma of the limb. In: Christine Clark, ed. Beromun, Second Expert Meeting. Barcelona, 2001:16–18.
Fraker D, Alexander H, Ross M, et al. A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma (IFN). Ann Surg Oncol 2002;9:S8.
Hill S, Fawcett WJ, Sheldon J, Soni N, Williams T, Thomas JM. Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg 1993;80:995–997.
Di Filippo F, Rossi CR, Vaglini M, et al. Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: results of a phase I study. J Immunother 1999;22:407–414.
Stehlin JS Jr. Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet 1969;129:305–308.
McBride CM. Sarcomas of the limbs. Results of adjuvant chemotherapy using isolation perfusion. Arch Surg 1974;109:304–308.
Sugarbaker EV, McBride CM. Survival and regional disease control after isolation-perfusion for invasive stage I melanoma of the extremities. Cancer 1976;37:188–198.
Casara D, Rubello D, Pilati PL, Scalerta R, Foletto M, Rossi CR. A simplified procedure for continuous intraoperative external monitoring of systemic leakage during isolated limb perfusion. Tumori 2002;88:S61–3.
Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905–910.
Lienard D, Eggermont AM, Koops HS, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999;9:491–502.
Rosenblum MG, Donato NJ, Gutterman JU. Characterization of human recombinant tumor necrosis factor-alpha antiproliferative effects on human cells in culture. Lymphokine Res 1988;7:107–117.
Buell JF, Reed E, Lee KB, et al. Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells. Ann Surg Oncol 1997;4:141–148.
de Wilt JH, ten Hagen TL, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AM. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000;82:1000–1003.
Robins HI, d’Oleire F, Kutz M, et al. Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8 degrees C hyperthermia. Cancer Lett 1995;89:55–62.
van der Veen AH, Wilt JH de, Eggermont AM, Tiel ST van, Seynhaeve AL, ten Hagen TL. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 2000;82:973–980.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rossi, C.R., Foletto, M., Mocellin, S. et al. Hyperthermic Isolated Limb Perfusion With Low-Dose Tumor Necrosis Factor-α and Melphalan for Bulky In-Transit Melanoma Metastases. Ann Surg Oncol 11, 173–177 (2004). https://doi.org/10.1245/ASO.2004.03.019
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1245/ASO.2004.03.019